Presentation Information
[BIP-05]Novel Features of a Phase 1b/2a Radiprodil Trial Advancing to Phase 3 in GRIN-Related Neurodevelopmental Disorder
Chin Russell1, Veenma Danielle2, Guerrini Renzo3, Leuchter Bruce1, Panzara Michael1 (1.GRIN Therapeutics, Inc., A Neurvati Neurosciences Company, New York, NY, USA, 2.Erasmus-MC Sophia, Rotterdam, The Netherlands, 3.Children's Hospital A. Meyer IRCCS-University of Florence, Florence, Italy)
Password required to view
Comment
To browse or post comments, you must log in.Log in